Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy

Shalin Rawal; Kamal Sharma; Aditya Shah; Shriya Bavishi; Cleris Christian; Parjanya Bhatt; Ashwati Konat

doi:10.3389/fcvm.2022.916705

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy

Front Cardiovasc Med. 2022 Jun 23:9:916705. doi: 10.3389/fcvm.2022.916705. eCollection 2022.

Authors

Shalin Rawal¹, Kamal Sharma², Aditya Shah¹, Shriya Bavishi¹, Cleris Christian¹, Parjanya Bhatt¹, Ashwati Konat³

Affiliations

¹ Intern MBBS, B. J. Medical College and Civil Hospital, Ahmedabad, India.
² Department of Cardiology, SAL Hospital, Ahmedabad, India.
³ Department of Zoology, Biomedical Technology, and Human Genetics, Gujarat University, Ahmedabad, India.

No abstract available

Keywords: Quality-Adjusted Life-Years (QALY); cost-effectiveness; dual pathway inhibitor; incremental cost-effectiveness ratio (ICER); rivaroxaban.

Publication types

Comment